(RTTNews) – CureVac N. V. (CVAC) shares rose more than 6% on Wednesday morning. The Tuesday after the bell, CureVac announced that it had introduced a phase 2a trial of its COVID-19 candidate vaccine.
The CVAC is currently $48. 57, up $2. 89 or $6. 33% on the Nasdaq.
The clinically staged biopharmaceutical company announced that the first player had received a dose in a phase 2a clinical trial of their COVID-19 candidate vaccine, CvnCoV.
He is taking place in Peru and Panama and will recruit a total of 690 healthy participants. Participants will receive two vaccines at 28-day intervals. Different dose grades will be studied to verify protection and evaluate the reactogenicity of the vaccine in the elderly.
The first complete knowledge for Phase 2a in the elderly is expected by the end of the fourth quarter of 2020.